Allogene Therapeutics Inc (ALLO)
EBITDA Growth
16.57%
Quarterly · Period ending:
ALLO EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported16.57%period ending
Latest reported16.57%period ending
ALLO Quarterly EBITDA YoY % (-1503850.00% → 16.57%)
Year-over-year change
High-resolution chart · PNG
ALLO ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| 16.5654% | |
| 30.1785% | |
| 36.9193% | |
| 39.7342% | |
| 24.1493% | |
| 8.0739% | |
| 17.925% | |
| -7.2741% | |
| 17.0329% | |
| 36.3007% | |
| 25.4165% | |
| 25.9472% | |
| -6.2957% | |
| -26.6591% | |
| -29.9507% | |
| -4.5244% | |
| -3.1027% | |
| -143.4485% | |
| -18.7071% | |
| -14.5342% | |
| -12.5706% | |
| 43.775% | |
| -0.2798% | |
| -23.3724% | |
| -36.7268% | |
| -55.5639% | |
| -97.2472% | |
| -35.44% | |
| 66.6979% | |
| -1,277.2045% | |
| -1,503,850% |